Research programme: embryonic stem cell therapies - ES Cell International
Alternative Names: ESI-014; ESI-017; ESI-035; ESI-049; ESI-051; ESI-053Latest Information Update: 05 Jul 2021
At a glance
- Originator
- Developer ES Cell International; Lineage Cell Therapeutics; University of California at Irvine
- Class Antihyperglycaemics; Cardiovascular therapies; Neural stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Heart failure; Huntington's disease
Most Recent Events
- 31 Mar 2021 ES Cell International in-licenses human embryonic stem cell lines from AgeX Therapeutics before March 2021
- 31 Mar 2021 ES Cell International has patent protection for embryonic stem cell therapeutics in USA, Australia, Israel, UK, Singapore, Japan
- 31 Mar 2021 ES Cell International has patents pending for embryonic stem cell therapies in USA and Europe